Главная
Study mode:
on
1
Intro
2
Non-small cell lung carcinomas
3
What are driver mutations?
4
RAS Signaling Pathway
5
KRAS Mutations
6
BRAF Mutations & Classes
7
Case #1 Pathology Findings
8
Case #1 Lab Findings
9
Case #2 pathology findings
10
Case #2 lab findings
11
Clinical Treatment and Update
12
Who's driving treatment? Two Co-occurring Driver Mutations in Primary Lung Adenocarcinoma
13
Acknowledgements
Description:
Explore a 14-minute conference talk from the 2022 Cancer Genomics Consortium Annual Meeting that delves into the complexities of co-occurring driver mutations in primary lung adenocarcinoma. Gain insights into non-small cell lung carcinomas, driver mutations, and the RAS signaling pathway. Examine KRAS and BRAF mutations, including BRAF mutation classes. Follow two case studies, analyzing their pathology and laboratory findings. Learn about clinical treatment approaches and updates for patients with multiple driver mutations. Understand the implications of co-occurring driver mutations on treatment decisions in lung adenocarcinoma. This presentation, delivered by Danielle Salari, recipient of the CGC 2022 Technologist Award, offers valuable knowledge for oncologists, pathologists, and researchers in the field of cancer genomics.

Two Co-occurring Driver Mutations in Primary Lung Adenocarcinoma - Who's Driving Treatment?

Cancer Genomics Consortium
Add to list
0:00 / 0:00